VRCAVerrica Pharmaceuticals Inc.

$56M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+2744.5% YoY

Gross Profit

$5M89.5% margin

Operating Income

-$15M-293.7% margin

Net Income

-$17M-332.0% margin

EPS (Diluted)

$-3.70

QoQ Revenue Growth

+35.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$52M

Total Liabilities

$65M

Stockholders' Equity

-$13M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$182,000	+2744.5%
Gross Profit	$5M	$46,000	+9976.1%
Operating Income	-$15M	-$12M	-30.9%
Net Income	-$17M	-$11M	-56.4%

Revenue Segments

Product

$5M94%

Collaboration

$285,0006%

VRCA Q2 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena